Aim: Alumina nanowell based disposable diagnostic biosensor for detecting and quantifying levels of prostate-specific antigen (PSA) from human serum has been designed, fabricated and tested.
Materials & Methods: The biosensors were designed by integrating nanoporous alumina membranes onto printed circuit board platforms, resulting in the generation of high-density nanowell arrays with gold base electrodes. The size and density of the nanowells were leveraged toward achieving sieving action for size-based exclusion of nonspecific molecules and size-based confinement of the target PSA molecules.
Results & Conclusion: We demonstrated PSA detection between 0.01 and 1000 ng/ml and detection and quantification of PSA from a 17 patient cohort validated using the Beckman Access system with >95% correlation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/NNM.15.100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mPDAC) or castration-resistant prostate cancer (mCRPC). Primary objectives were to evaluate safety and tolerability and determine the recommended phase 2 dose/schedule (RP2D). Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid.
View Article and Find Full Text PDFClinical assessment of urinary prostate cancer antigen 3 in Chinese population: a large-scale, prospective and multicenter study.
World J Surg Oncol
December 2024
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: To assess the clinical utility of PCA3 in the diagnostic accuracy, the correlation between PCA3 and biopsy or pathological characteristics and the performance of PCA3 to reduce the unnecessary biopsies in Chinese population.
Methods: A prospective study including patients with indication of prostate biopsies from 4 centers was conducted. All patients underwent PCA3 urine tests and prostate biopsies.
Rethinking the use of redox probes for the detection of electroactive proteins with electrochemical sensors modified with molecularly imprinted polymers.
Biosens Bioelectron
December 2024
Cnam, SATIE Laboratory, UMR, CNRS 8029, 292 rue Saint Martin, 75003, Paris, France. Electronic address:
This study aims to demonstrate that redox couples, regardless of their electrical charges, are unnecessary for detecting and quantifying electroactive proteins using an electrochemical sensor functionalized with a molecularly imprinted polymer. Our approach involved designing a polydopamine imprinted biosensor for detecting bovine serum albumin as the model protein. Electrochemical measurements were conducted in a phosphate-buffered solution (PBS) and solutions containing the negatively charged hexacyanoferrate, the neutral ferrocene, or the positively charged hexaammineruthenium (III) probes.
View Article and Find Full Text PDFSynthetic diffusion-weighted imaging in prostate cancer diagnosis: a comparison study with different B-value combinations.
Clin Radiol
December 2024
Department of Radiology, The Second Affiliated Hospital of Nanjing Medical University, Nan Jing, PR China. Electronic address:
Aim: To evaluate the impact of different b-value combinations on synthetic diffusion-weighted imaging (sDWI) and determine the sDWI with an optimal b-value combination for prostatic cancer (PCa) diagnosis.
Material And Methods: A retrospective analysis of 68 patients with abnormal prostate-specific antigen (PSA) was conducted. The sDWI images with b value of 1500 s/mm were separately reconstructed by the following five b-value combinations: b=0, 200s/mm (sDWI); b=600, 800s/mm (sDWI); b=0, 600s/mm (sDWI); b=200, 800s/mm sDWI); b=0, 800s/mm (sDWI).
The Trends, Clinicopathological Features, and Treatment Outcomes of Patients with Prostate Cancer in Lokoja, Nigeria.
J West Afr Coll Surg
August 2024
Division of Urology, Department of Surgery, College of Health Sciences, University of Abuja, Abuja, Nigeria.
Background: Prostate cancer (PCa) was the most common noncutaneous cancer among Nigerian men in 2020. Despite this high incidence, documented rates may be an underestimation.
Objectives: This study aimed to determine the hospital incidence rate, trends, and characterise the clinicopathologic features, and treatment outcomes of patients with PCa in our institution.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!